Aptevo Therapeutics Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended June 30, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period fromtoCommission File Number: 001-37746 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in its Charter) 81-1567056(I.R.S. EmployerIdentification No.) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and"emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)3Condensed Consolidated Balance Sheets3Condensed Consolidated Statements of Operations4Condensed Consolidated Statements of Cash Flows5Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)6Notes to Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures About Market Risk25Item 4.Controls and Procedures25 PART II.OTHER INFORMATIONItem 1.Legal Proceedings26Item 1A.Risk Factors26Item 2.Unregistered Sales of Equity Securities and Use of Proceeds59Item 3.Defaults Upon Senior Securities59Item 4.Mine Safety Disclosures59Item 5.Other Information59Item 6.Exhibits60Signatures61 In this Quarterly Report on Form 10-Q, "we," "our," "us," "Aptevo," and "the Company" refer to Aptevo Therapeutics Inc. and,where appropriate, its consolidated subsidiaries. PART I—FINANCIAL INFORMATION Aptevo Therapeutics Inc.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except share and per share amounts, unaudited) Aptevo Therapeutics Inc.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except share and per share amounts, unaudited) Aptevo Therapeutics Inc.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands, unaudited) Aptevo Therapeutics Inc.Notes to Unaudited Condensed Consolidated Financial Statements Note 1. Nature of Business and Significant Accounting Policies Organization and Liquidity Aptevo Therapeutics Inc. (Aptevo, we, us, or the Company) is a clinical-stage biotechnology company developing novelmultispecific immunotherapies for the treatment of cancer. The Company’s lead clinical candidate, mipletamig, is currently beingevaluated in frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Aptevo’s pipeline isgenerated from its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms and includes bispecific and trispecific candidatesdesigned to create multiple oncology value drivers across hematologic malignancies and solid tumors. In preclinical development,Aptevo is advancing APVO451, a nectin-4-targeted trispecific immunotherapy candidate for solid tumors and is pursuing strategicopportunitiesin radiopharmaceutical therapeutics to extend its tumor-targeting expertise into additional cancer treatmentapproaches. For more information, visit www.aptevotherapeutics.com. We are currently trading on the Nasdaq Capital Market under the symbol "APVO."The accompanying financial statements have been prepared on a basis that assumes we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. Theconsolidated financial statements do not include any adjustments that might result from the outcome of the uncertainty of ourability to continue as a going concern, nor do they include